| Trial Title | Who can participate? | Where is the trial open? | What question is the trial asking? | Full trial information |
|---|---|---|---|---|
HN009:Randomised Phase II/III Trial of Radiation with High-dose cisplatin (100mg/m2) every three weeks versus radiation with low-dose weekly cisplatin (40mg/m2) for patients with locoregionally advanced squamous cell carcinoma of the head and neck. |
You can take part in this study if you have been diagnosed with squamous cell head and neck cancer (SCCHN) and if you are eligible to receive high-dose concurrent chemo-radiation with cisplatin. Your doctor will decide your eligibility based on screening tests such as blood tests. |
|
The purpose of this study is to compare two different ways of giving chemotherapy (cisplatin) along with radiation treatment for people with locally advanced squamous cell head and neck cancer (SCCHN). Patients will either receive their chemotherapy on a weekly basis or they will receive a higher dose of chemotherapy every three weeks. The study aims to find out if giving low-dose cisplatin once a week causes fewer short-term side effects than giving high-dose cisplatin every 3 weeks |
|
CTRIAL 25-64 SPAREKID:Multi-markers risk assessment of kidney sensitivity to injury to personalize |
All patients planned to receive the following chemotherapy drugs: cisplatin, methotrexate, carboplatin or oxaliplatin. Patients with end-stage kidney disease or patient who are on dialysis cannot take part. |
|
The main goal of the study is to find out how accurate a new kidney injury (AKI) biomarker test is at predicting kidney problems after the first cycle of cancer chemotherapy. All that’s required is that a small amount of extra blood is collected at the same time you’re already having blood tests, and that urine samples are also provided at those times. All other information needed for the study will be taken from your medical records, so no additional appointments or procedures are needed. |